SCHEMBL4292765

SCHEMBL4292765

NC(=O)c1cccc2ccc[c]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 11/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
PDPK1 O15530 1/20 0.44
PLK4 O00444 1/20 0.42
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
MAP4K4 O95819 1/20 0.42
CSF1R P07333 1/20 0.42
RET P07949 1/20 0.42
FGFR1 P11362 1/20 0.42
PDGFRA P16234 1/20 0.42
LTK P29376 1/20 0.42
KDR P35968 1/20 0.42
MAP2K2 P36507 1/20 0.42
FLT3 P36888 1/20 0.42
CSNK1A1 P48729 1/20 0.42
PRKX P51817 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206060 0.82 NR4A1 (0.48) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL7793793 0.81 MAOB (0.37) PARP1KDM4EALDH1A1GAAHPGD
SCHEMBL10915695 0.74 KDM4E (0.50) PARP1KDM4EALDH1A1GAAPDPK1
SCHEMBL10482945 0.74 KDM4E (0.45) PARP1KDM4EALDH1A1GAAPDPK1
SCHEMBL2584051 0.73 PARP1 (0.43) PARP1ALDH1A1PLK4MAP4K4PRKX
SCHEMBL5748948 0.73 KDM4E (0.63) PARP1KDM4EALDH1A1GAAPDPK1
SCHEMBL5748816 0.73 KDM4E (0.63) PARP1KDM4EALDH1A1GAAPDPK1
SCHEMBL14660905 0.72 KDM4E (0.43) PARP1KDM4EALDH1A1GAAMAPT
SCHEMBL3980872 0.72 KDM4E (0.43) PARP1KDM4EALDH1A1GAAPDPK1
SCHEMBL1893396 0.72 PARP1 (0.44) PARP1KDM4EALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060281897-A1 Potentialization of the activation of high molecular weight prodrugs DIATOS S.A. (FR) 2006-12-14 US claimed
US-20090220529-A1 Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker DIATOS, S.A. (FR) 2009-09-03 US disclosed
EP-1993608-A1 ANTICANCER DRUGS CONJUGATED TO ANTIBODY VIA AN ENZYME CLEAVABLE LINKER Diatos (FR) 2008-11-26 EP disclosed
WO-2008120098-A2 PEPTIDE PRODRUGS DIATOS (FR) 2008-10-09 WO disclosed
EP-1977765-A1 Peptide prodrugs Diatos (FR) 2008-10-08 EP disclosed
WO-2007105027-A1 ANTICANCER DRUGS CONJUGATED TO ANTIBODY VIA AN ENZYME CLEAVABLE LINKER DIATOS (FR) 2007-09-20 WO disclosed
US-20060293503-A1 Polyaminopyridines and method for producing same SUMITOMO SEIKA CHEMICALS CO., LTD (JP) 2006-12-28 US disclosed
US-20060281897-A1 Potentialization of the activation of high molecular weight prodrugs DIATOS S.A. (FR) 2006-12-14 US disclosed
EP-1669390-A1 POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281897-A1 Potentialization of the activation of high molecular weight prodrugs CD44, MMP12, FOLH1 PARP1 139/4885KDM4E 3907/4885ALDH1A1 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.